Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH.
This article continues a series of reports on recent research developments in the field of heart failure. Reports of two key presentations made at the European Society of Cardiology Heart Failure Update meeting held in Oslo, Norway from 8 to 11 June 2002, are included in this article. Summaries of the results of the RENEWAL (RENAISSANCE and RECOVER) and ATTACH studies, presented at the Hot Line sessions held during the meeting are reported.
Coletta
A P
AP
Department of Academic Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU15 5JQ, UK. a.p.coletta@hull.ac.uk
Clark
A L
AL
Banarjee
P
P
Cleland
J G F
JG
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000068800:Etanercept; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D000069285:Infliximab; D009664:Norway; D016032:Randomized Controlled Trials as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012955:Societies, Medical; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept